MDT
NYSEMedtronic plc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Price$80.00-0.20 (-0.26%)
01:30 PM07:45 PM
News · 26 weeks81+267%
2025-11-022026-04-26
Mix5090d
- Other21(42%)
- Insider17(34%)
- SEC Filings4(8%)
- Analyst3(6%)
- Offering3(6%)
- Dividends2(4%)
Latest news
25 items- PRFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyAtrioventricular Interval Modulation ("AVIM") Therapy Food and Drug Administration ("FDA") Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT TrialThe addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medicationBreakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment ("NTAP") and Tr
- INSIDERChief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Lofton Kevin E was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 23% to 10,140 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Jellison William R was granted 1,444 units of Ordinary Shares, increasing direct ownership by 29% to 6,444 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Lee Joon Sup was granted 1,803 units of Ordinary Shares (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Lewis Gregory P was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 49% to 5,754 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Hogan Randall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 48,998 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Groetelaars John P was granted 1,444 units of Ordinary Shares (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Donnelly Scott C covered exercise/tax liability with 207 units of Ordinary Shares and was granted 2,111 units of Ordinary Shares, increasing direct ownership by 9% to 23,679 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Fonseca Lidia was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 33% to 7,644 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- INSIDERDirector Arnold Craig was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 5% to 42,185 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- PRWhy Medtech Giants Are Quietly Paying Up for AI DiagnosticsISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Medtronic (NYSE:MDT), Danaher (NYSE:DHR
- PRMedtronic announces CE Mark for Stealth AXiS™ surgical systemFollowing recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across EuropeGALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into one single, intelligent system. The Stealth AXiS™ system is indicated for spine and cranial procedures, highlighting the platform's scalability across multiple surgical specialties for Medtronic. "Re
- SECMedtronic plc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Medtronic plc (0001613103) (Filer)
- PRMedtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continuesHRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of the Sphere-9 catheter for treatment of VT; U.S. pivotal trial approved by FDANew at HRS: data show consistent durability for the Sphere-360 catheter across patient anatomies; Sphere-360 approved in CE Mark geographiesFirst patients enrolled in Conquer-AF trial to evaluate the Sphere-9 catheter for repeat atrial fibrillation proceduresGALWAY, Ireland and CHICAGO, April 25, 2026 /PRNewswire/ -- Medtronic plc, (NYSE:MDT), a global leader in healthcare technology, today announc
- PROrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio
- PRMedtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular diseaseCathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessmentGALWAY, Ireland, April 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition
- PRThe Infrastructure Play Hiding in Plain Sight Across Cardiac CareVANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra
- PRMedtronic to announce financial results for its fourth quarter and full fiscal year 2026GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at
- PRTelix Strengthens Board with Additional Director AppointmentsMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)
- PRMedtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT ProceduresGALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform."Cranial procedures req
- SECMedtronic plc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Medtronic plc (0001613103) (Filer)
MDT FAQ
6 questionsWhat does Medtronic plc. do?
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered...Where does MDT stock trade?
Medtronic plc. (MDT) is listed on NYSE.What sector and industry is MDT in?
Medtronic plc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.What are analysts saying about MDT?
Medtronic plc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-02-13.What companies are similar to MDT?
Notable peers in the same industry include MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), TMDX (TransMedics Group Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare MDT side-by-side with any of them on Quantisnow.How can I track MDT on Quantisnow?
Quantisnow aggregates Medtronic plc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDT to receive live email and push alerts on every new disclosure.